Market research

YARW Yarrow Bioscience Inc

NASDAQ USD Healthcare

Latest close

— —

Loading market data…

Test a moving-average rule with historical data.

Market cap: 97M
P/E ratio: Not available
Analyst target: 57
Dividend yield: 0.0%
Beta: 2.08

Loading price history…

Profile

Company facts

Exchange: NASDAQ
Currency: USD
Sector: Healthcare
Industry: Biotechnology
ISIN: US92941V4077
Market cap: 97M
P/E ratio: Not available
Analyst target: 57
Dividend yield: 0.0%
Beta: 2.08

About

About Yarrow Bioscience Inc

Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.

Visit company website

Reported results

Fundamentals

Open this section to load reported financial history.

Annual returns

No comments yet

Start a focused discussion about YARW.

YARW Yarrow Bioscience Inc

Price & volume

Company facts

About Yarrow Bioscience Inc

Fundamentals

Earnings

Cash flow

Profitability

Valuation

Performance

Annual returns

Investor discussion

No comments yet